1. Home
  2. LXEO vs CGEM Comparison

LXEO vs CGEM Comparison

Compare LXEO & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

HOLD

Current Price

$6.59

Market Cap

731.3M

Sector

N/A

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$11.68

Market Cap

780.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LXEO
CGEM
Founded
2017
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
731.3M
780.4M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
LXEO
CGEM
Price
$6.59
$11.68
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
9
Target Price
$18.60
$28.33
AVG Volume (30 Days)
911.2K
679.4K
Earning Date
03-23-2026
03-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.45
$5.68
52 Week High
$10.99
$13.43

Technical Indicators

Market Signals
Indicator
LXEO
CGEM
Relative Strength Index (RSI) 33.85 50.59
Support Level $6.73 $11.36
Resistance Level $7.31 $12.55
Average True Range (ATR) 0.46 0.86
MACD -0.00 -0.10
Stochastic Oscillator 17.16 17.87

Price Performance

Historical Comparison
LXEO
CGEM

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Share on Social Networks: